Miller fisher syndrome associated with immunotherapy for metastatic melanoma

Jonathan J.D. Baird-Gunning; Dinushi Weerasinghe; Matthew Silsby; Yash Gawarikar; Matteo S. Carlino; Jessica L. Smith; Steve Vucic

doi:10.1177/1941874418778957

Miller fisher syndrome associated with immunotherapy for metastatic melanoma

Jonathan J.D. Baird-Gunning, Dinushi Weerasinghe, Matthew Silsby, Yash Gawarikar, Matteo S. Carlino, Jessica L. Smith, Steve Vucic

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Abstract

Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, resulting in upregulation of the host immune response to cancer cells. There is increasing recognition of immune-mediated adverse events associated with immune therapies in patients with cancer. We present a case report of a patient who developed Miller Fisher syndrome associated with these therapies for metastatic melanoma along with a discussion of its management.

Original language	English
Pages (from-to)	191-193
Number of pages	3
Journal	Neurohospitalist
Volume	8
Issue number	4
DOIs	https://doi.org/10.1177/1941874418778957
Publication status	Published - Oct 2018
Externally published	Yes

Bibliographical note

Publisher Copyright:
© The Author(s) 2018.

Keywords

CTLA-4 receptor
Immunotherapy
Melanoma
Miller-fisher syndrome
PD-1 receptor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/1941874418778957

Cite this

@article{4bbe601d522a44a9b1eaff281479c1f3,

title = "Miller fisher syndrome associated with immunotherapy for metastatic melanoma",

abstract = "Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, resulting in upregulation of the host immune response to cancer cells. There is increasing recognition of immune-mediated adverse events associated with immune therapies in patients with cancer. We present a case report of a patient who developed Miller Fisher syndrome associated with these therapies for metastatic melanoma along with a discussion of its management.",

keywords = "CTLA-4 receptor, Immunotherapy, Melanoma, Miller-fisher syndrome, PD-1 receptor",

author = "Baird-Gunning, {Jonathan J.D.} and Dinushi Weerasinghe and Matthew Silsby and Yash Gawarikar and Carlino, {Matteo S.} and Smith, {Jessica L.} and Steve Vucic",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2018.",

year = "2018",

month = oct,

doi = "10.1177/1941874418778957",

language = "English",

volume = "8",

pages = "191--193",

journal = "Neurohospitalist",

issn = "1941-8744",

publisher = "SAGE Publications Inc.",

number = "4",

}

TY - JOUR

T1 - Miller fisher syndrome associated with immunotherapy for metastatic melanoma

AU - Baird-Gunning, Jonathan J.D.

AU - Weerasinghe, Dinushi

AU - Silsby, Matthew

AU - Gawarikar, Yash

AU - Carlino, Matteo S.

AU - Smith, Jessica L.

AU - Vucic, Steve

N1 - Publisher Copyright: © The Author(s) 2018.

PY - 2018/10

Y1 - 2018/10

N2 - Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, resulting in upregulation of the host immune response to cancer cells. There is increasing recognition of immune-mediated adverse events associated with immune therapies in patients with cancer. We present a case report of a patient who developed Miller Fisher syndrome associated with these therapies for metastatic melanoma along with a discussion of its management.

AB - Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, resulting in upregulation of the host immune response to cancer cells. There is increasing recognition of immune-mediated adverse events associated with immune therapies in patients with cancer. We present a case report of a patient who developed Miller Fisher syndrome associated with these therapies for metastatic melanoma along with a discussion of its management.

KW - CTLA-4 receptor

KW - Immunotherapy

KW - Melanoma

KW - Miller-fisher syndrome

KW - PD-1 receptor

UR - http://www.scopus.com/inward/record.url?scp=85057904872&partnerID=8YFLogxK

U2 - 10.1177/1941874418778957

DO - 10.1177/1941874418778957

M3 - Article

AN - SCOPUS:85057904872

SN - 1941-8744

VL - 8

SP - 191

EP - 193

JO - Neurohospitalist

JF - Neurohospitalist

IS - 4

ER -

Miller fisher syndrome associated with immunotherapy for metastatic melanoma

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this